Embracing patient choice [5]

British Journal of Psychiatry

Volumn 201, Issue 6, 2012, Pages 493-494

  Francey, Shona M ^a,b   McGorry, Patrick ^a,b   Nelson, Barnaby ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MELBOURNE HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

DISEASE SEVERITY; HUMAN; LETTER; PSYCHOSIS; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; DECISION MAKING; NOTE; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CHOICE BEHAVIOR; HUMANS; SCHIZOPHRENIA;

EID: 84870363693     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.201.6.493a     Document Type: Letter

References (3)

1. Morrison AP, Hutton P, Shiers D, Turkington D. Antipsychotics: is it time to introduce patient choice? Br J Psychiatry 2012; 201: 83-4.
2. Francey SM, Nelson B, Thompson A, Parker AG, Kerr M, Macneil C, et al. Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of the benefits, risks, neurobiology and ethic in the era of early intervention. Schizophr Res 2010; 19: 1-10.
3. McGorry PD. Issues for DSM-V: clinical staging: a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry. Am J Psychiatry 2007; 164: 859-60. (Pubitemid 46972899)